Calculate the percentage of diclofenac related compound A in relation to the quantity of diclofenac so-dium in the portion of Tablets taken:

Result = 
$$(r_U/r_S) \times (C_S/C_U) \times 100$$

 $\mathbf{r}_{\mathsf{U}}$ = peak response of diclofenac related compound A from the Sample solution

= peak response of diclofenac related  $r_s$ compound A from the Standard solution

= concentration of USP Diclofenac Related  $\mathsf{C}_\mathsf{S}$ Compound A RS in the Standard solution

 $\mathsf{C}_\mathsf{U}$ = nominal concentration of diclofenac sodium in the Sample solution (mg/mL)

Calculate the percentage of each impurity other than diethyl phthalate, if present, in relation to the diclofenac sodium in the portion of Tablets taken:

Result = 
$$(r_U/r_S) \times (C_S/C_U) \times 100$$

= peak response for each impurity from the  $r_{U}$ Sample solution

= peak response of diclofenac related rς compound A from the Standard solution

= concentration of USP Diclofenac Related  $\mathsf{C}_{\mathsf{S}}$ Compound A RS in the Standard solution (mg/mL)

 $C_U$ = nominal concentration of diclofenac sodium in the Sample solution (mg/mL)

Acceptance criteria

Individual impurities: NMT 0.5% of diclofenac related compound A; NMT 1.0% of any other individual impurity

Total impurities: NMT 1.5%

## ADDITIONAL REQUIREMENTS

• PACKAGING AND STORAGE: Preserve in tight, light-resistant

**USP R**EFERENCE **S**TANDARDS  $\langle 11 \rangle$ 

USP Diclofenac Sodium RS USP Diclofenac Related Compound A RS *N*-(2,6-Dichlorophenyl)indolin-2-one. C<sub>14</sub>H<sub>9</sub>Cl<sub>2</sub>NO 278.14

# **Diclofenac Sodium Extended-Release Tablets**

## **DEFINITION**

Diclofenac Sodium Extended-Release Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of diclofenac sodium (C<sub>14</sub>H<sub>10</sub>Cl<sub>2</sub>NNaO<sub>2</sub>).

## **IDENTIFICATION**

• A. The retention time of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

• B. THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST

⟨201⟩

Standard solution: 2.0 mg/mL of USP Diclofenac Sodium RS in methanol. [NOTE—Shake by mechanical means for 10 min before makeup to final volume.]

Sample solution: Equivalent to 2.0 mg/mL of diclofenac sodium from a portion of the powder (NLT 10 Tablets) in methanol. [NOTE—Sonicate for 10 min, and shake by mechanical means for 10 min before makeup to final volume. Centrifuge this solution, and use the clear supernatant.]

Developing solvent system: Methanol, toluene, and glacial acetic acid (8:12:0.1)

### **ASSAY**

#### PROCEDURE

[NOTE—Protect the Standard solution, System suitability

solution, and Sample solution from light.]

Diluent: Methanol and water (7:3)

Buffer: 0.01 M phosphoric acid and 0.01 M monobasic sodium phosphate. Adjust with appropriate component to a pH of 2.5.

Mobile phase: Methanol and Buffer (7:3)

Standard solution: 0.5 mg/mL of USP Diclofenac Sodium RS in *Diluent* 

**Resolution solution:** 20 μg/mL of diethyl phthalate, 7.5 μg/mL of USP Diclofenac Related Compound A RS, and 0.75 mg/mL of USP Diclofenac Sodium RS in

Sample solution: Powder NLT 20 Tablets, and transfer a weighed portion of the powder, equivalent to 100 mg of diclofenac sodium, to a 200-mL volumetric flask, and add 150 mL of *Diluent*. Heat on a steam bath for 3–5 min, and sonicate for 20 min. Cool to room temperature, and dilute with Diluent to volume. Place the flask in an ice bath for 45 min, shaking occasionally to precipitate out any undissolved waxy material. Pass a portion of the chilled solution through a filter of 0.45-um or finer pore size. Allow the filtrate to reach room temperature before using

Chromatographic system

(See Chromatography (621), System Suitability.)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 25-cm; packing L7

Flow rate: 1 mL/min Injection size: 10 μL System suitability

Samples: Standard solution and Resolution solution [NOTE—The relative retention times for diethyl phthalate, diclofenac related compound A, and diclofenac are 0.5, 0.6, and 1.0, respectively.]

Suitability requirements
Resolution: NLT 2.2 between the diethyl phthalate and diclofenac related compound A peaks, and NLT 3.8 between the diclofenac related compound A and

diclofenac peaks, Resolution solution Relative standard deviation: NMT 2.0% for diclofenac, Standard solution

Analysis

Samples: Standard solution and Sample solution Calculate the percentage of C<sub>14</sub>H<sub>10</sub>Cl<sub>2</sub>NNaO<sub>2</sub> in the portion of Tablets taken:

Result = 
$$(r_U/r_S) \times (C_S/C_U) \times 100$$

= peak response of diclofenac from the Sample ru

= peak response of diclofenac from the Standard  $r_s$ solution

= concentration of USP Diclofenac Sodium RS in  $\mathsf{C}_\mathsf{S}$ the Standard solution (mg/mL)

 $C_{U}$ = nominal concentration of diclofenac sodium in the Sample solution (mg/mL)

Acceptance criteria: 90.0%-110.0%

## **PERFORMANCE TESTS**

**Dissolution**  $\langle 711 \rangle$ 

Test 1

Medium: 0.05 M phosphate buffer, pH 7.5; 900 mL

Apparatus 2: 50 rpm; use wire sinkers. Times: 1, 5, 10, 16, and 24 h Detector: UV 276 nm

Standard solution: USP Diclofenac Sodium RS in

Medium

Analysis: Pass portions of the solution under test through a suitable filter. Dilute with Medium, if necesconcentration similar to that of the Standard



**Tolerances:** The percentages of the labeled amount of C<sub>14</sub>H<sub>10</sub>Cl<sub>2</sub>NNaO<sub>2</sub> dissolved at the times specified conform to Acceptance Table 2.

Time (h)	Amount Dissolved
1	15%–35%
5	45%–65%
10	65%–85%
16	75%–95%
24	NLT 80%

**Test 2:** If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 2.

Medium, Apparatus, and Analysis: Proceed as directed for Dissolution Test 1.

Times: 1, 2, 4, 6, and 10 h

Tolerances: The percentages of the labeled amount of C<sub>14</sub>H<sub>10</sub>Cl<sub>2</sub>NNaO<sub>2</sub> dissolved at the times specified conform to Acceptance Table 2.

Time (h)	Amount Dissolved
1	NMT 28%
2	20%–40%
4	35%–60%
6	50%–80%
10	NLT 65%

**Test 3:** If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 3. Medium and Analysis: Proceed as directed for Dissolu-

tion Test 1.

form to Acceptance Table 2.

Apparatus 1: 100 rpm Times: 2, 4, 8, and 16 h Tolerances: The percentages of the labeled amount of C<sub>14</sub>H<sub>10</sub>Cl<sub>2</sub>NNaO<sub>2</sub> dissolved at the times specified con-

Time (h)	Amount Dissolved
2	22%–42%
4	34%–61%
8	52%-82%
16	NLT 73%

Test 4: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 4.

**Medium** and **Analysis**: Proceed as directed for *Test 1*.

Apparatus 1: 100 rpm
Times: 2, 4, 8, and 16 h
Tolerances: The percentages of the labeled amount of C<sub>14</sub>H<sub>10</sub>Cl<sub>2</sub>NNaO<sub>2</sub> dissolved at the times specified conform to Acceptance Table 2.

Time (h)	Amount Dissolved
2	20%–40%
4	35%-55%
8	60%–85%
16	NLT 85%

• Uniformity of Dosage Units (905): Meet the requirements

### **IMPURITIES**

**Organic Impurities** 

PROCEDURE

Diluent, Buffer, Mobile phase, Resolution solution, male colution. Chromatographic cyctem, and Sys **Standard stock solution:** 0.8 mg/mL of USP Diclofenac Related Compound A RS in Diluent

Standard solution: 4 µg/mL of USP Diclofenac Related Compound A RS, made by diluting a measured volume of Standard stock solution with Diluent

System suitability solution: 0.5 mg/mL of USP Diclofenac Sodium RS in Diluent

System suitability

Samples: Resolution solution and System suitability solution

[NOTE—The relative retention times for diethyl phthalate, diclofenac related compound A, and diclofenac are 0.5, 0.6, and 1.0, respectively.]

**Suitability requirements** 

**Resolution:** NLT 2.2 between the diethyl phthalate and diclofenac related compound A peaks; and NLT 3.8 between the diclofenac related compound A

and the diclofenac peaks, Resolution solution Standard deviation: NMT 2.0% for the diclofenac peak, System suitability solution

Analysis

Samples: Sample solution and Standard solution Calculate the percentage of each impurity in the portion of Tablets taken:

Result = 
$$(r_U/r_S) \times (C_S/C_U) \times 100$$

 $\mathbf{r}_{\mathsf{U}}$ = peak response for any impurity from the Sample solution

 $\mathbf{r}_{\mathsf{S}}$ = peak response for USP Diclofenac Related Compound A RS from the Standard solution

 $C_{\text{S}}$ = concentration (mg/mL) of USP Diclofenac Related Compound A RS in the Standard solution

 $C_U$ = concentration (mg/mL) of diclofenac sodium in the Sample solution

Acceptance criteria

Total impurities: NMT 1.5%

### ADDITIONAL REQUIREMENTS

 PACKAGING AND STORAGE: Preserve in well-closed containers. Store at controlled room temperature, and protect from light.

**LABELING:** When more than one *Dissolution* test is given, the labeling states the test used only if Test 1 is not used.

**USP REFERENCE STANDARDS** (11)

USP Diclofenac Sodium RS USP Diclofenac Related Compound A RS *N*-(2,6-Dichlorophenyl)indolin-2-one. C<sub>14</sub>H<sub>9</sub>Cl<sub>2</sub>NO 278.14

## Dicloxacillin Sodium

 $C_{19}H_{16}CI_{2}N_{3}NaO_{5}S\cdot H_{2}O \quad 510.32$ 

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(2,6-dichlorophenyl)-5-methyl-

4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, monohydrate, [2S-(2 $\alpha$ ,5 $\alpha$ ,6 $\beta$ )]-

Monosodium (2*S*,5*R*,6*R*)-6-[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate monohydrate [13412-64-1]

Anhydrous 492.32 [343-55-5].

